Viking Therapeutics 将来の成長

Future 基準チェック /26

Viking Therapeuticsの収益は年間1.8%で減少すると予測されていますが、年間収益は年間78.9%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に-23% 2%なると予測されています。

主要情報

-1.8%

収益成長率

2.0%

EPS成長率

Biotechs 収益成長	28.5%
収益成長率	78.9%
将来の株主資本利益率	-23.0%
アナリストカバレッジ	Good
最終更新日	26 Nov 2024

今後の成長に関する最新情報

Recent updates

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Nov 04

Viking Therapeutics: Lots Of Positives

Oct 28

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13

Viking Therapeutics announces senior management appointments

Jan 06

Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Dec 09

Viking Therapeutics: Progressing Steadily, But Concerns Remain

Nov 29

業績と収益の成長予測

NasdaqCM:VKTX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	27	-206	-252	-223	11
12/31/2025	2	-169	-196	-156	12
12/31/2024	N/A	-108	-114	-90	13
9/30/2024	N/A	-99	-74	-74	N/A
6/30/2024	N/A	-97	-72	-72	N/A
3/31/2024	N/A	-94	-55	-55	N/A
12/31/2023	N/A	-86	-73	-73	N/A
9/30/2023	N/A	-81	-67	-67	N/A
6/30/2023	N/A	-74	-61	-61	N/A
3/31/2023	N/A	-72	-63	-63	N/A
12/31/2022	N/A	-69	-48	-48	N/A
9/30/2022	N/A	-62	-50	-50	N/A
6/30/2022	N/A	-59	-47	-47	N/A
3/31/2022	N/A	-57	-47	-47	N/A
12/31/2021	N/A	-55	-48	-48	N/A
9/30/2021	N/A	-54	-41	-41	N/A
6/30/2021	N/A	-50	-35	-35	N/A
3/31/2021	N/A	-44	-28	-28	N/A
12/31/2020	N/A	-39	-22	-22	N/A
9/30/2020	N/A	-36	-28	-28	N/A
6/30/2020	N/A	-32	-26	-26	N/A
3/31/2020	N/A	-31	-26	-26	N/A
12/31/2019	N/A	-26	-25	-25	N/A
9/30/2019	N/A	-24	-16	-16	N/A
6/30/2019	N/A	-24	-18	-18	N/A
3/31/2019	N/A	-23	-17	-17	N/A
12/31/2018	N/A	-22	-19	-19	N/A
9/30/2018	N/A	-21	-20	-20	N/A
6/30/2018	N/A	-20	N/A	-18	N/A
3/31/2018	N/A	-19	N/A	-17	N/A
12/31/2017	N/A	-21	N/A	-15	N/A
9/30/2017	N/A	-20	N/A	-13	N/A
6/30/2017	N/A	-18	N/A	-13	N/A
3/31/2017	N/A	-16	N/A	-12	N/A
12/31/2016	N/A	-15	N/A	-11	N/A
9/30/2016	N/A	-16	N/A	-12	N/A
6/30/2016	N/A	-17	N/A	-13	N/A
3/31/2016	N/A	-21	N/A	-11	N/A
12/31/2015	N/A	-23	N/A	-9	N/A
9/30/2015	N/A	-17	N/A	-6	N/A
6/30/2015	N/A	-12	N/A	-3	N/A
3/31/2015	N/A	-27	N/A	-2	N/A
12/31/2014	N/A	-22	N/A	-2	N/A
9/30/2014	N/A	-23	N/A	-1	N/A
6/30/2014	N/A	-23	N/A	-1	N/A
3/31/2014	N/A	0	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VKTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VKTX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: VKTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VKTXの収益 ( 78.9% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: VKTXの収益 ( 78.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VKTX 3 年以内に赤字になると予測されています。

Viking Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 14% to US$108

Price target increased by 11% to US$40.89

Price target increased by 8.8% to US$37.00

Price target increased by 9.1% to US$36.33

Price target increased by 7.5% to US$31.50

Price target increased by 12% to US$30.80

Recent updates

New major risk - Revenue and earnings growth

Viking Therapeutics, Inc. Presents Results from Phase 2b VOYage Study of VOYage Study of Voyage Study of Voyage

New major risk - Revenue and earnings growth

Viking Therapeutics, Inc. Announces Reports New Data from VK2735 Obesity Program at ObesityWeek 2024

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Viking Therapeutics to Highlight Clinical Data from VENTURE Phase 2 Study of Subcutaneous Vv2735 in Obese Patients and Phase 1 Trial of Oral Vv2735 in Healthy Subjects to Be Presented

Viking Therapeutics: Lots Of Positives

Independent Director exercised options and sold US$1.2m worth of stock

Viking Therapeutics, Inc. to Report Q3, 2024 Results on Oct 23, 2024

Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

President notifies of intention to sell stock

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Independent Director exercised options and sold US$1.0m worth of stock

President recently sold US$6.7m worth of stock

President notifies of intention to sell stock

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Viking Therapeutics, Inc. to Report Q2, 2024 Results on Jul 24, 2024

Viking Therapeutics, Inc. Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists At 84th Scientific Sessions of the American Diabetes Association

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2B Voyage Study of Vk2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (Nash)

New major risk - Revenue and earnings growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics, Inc. to Report Q1, 2024 Results on Apr 24, 2024

Viking Therapeutics, Inc., Annual General Meeting, May 21, 2024

Viking Therapeutics: Future Weight Loss Heavyweight?

Price target increased by 14% to US$108

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Viking Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $550.035 million.

Viking Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

New major risk - Share price stability

Price target increased by 11% to US$40.89

Price target increased by 8.8% to US$37.00

President notifies of intention to sell stock

Price target increased by 9.1% to US$36.33

New major risk - Revenue and earnings growth

Viking Therapeutics, Inc. to Report Q4, 2023 Results on Feb 07, 2024

President notifies of intention to sell stock

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Chief Financial Officer recently sold US$269k worth of stock

Chief Financial Officer notifies of intention to sell stock

New minor risk - Share price stability

Viking Therapeutics, Inc. Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting 2023

Viking Therapeutics, Inc. to Report Q3, 2023 Results on Oct 25, 2023

Viking Therapeutics, Inc. Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist Vv2735 in Oral Presentation At Obesityweek 2023

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics, Inc. Announces Initiation of Phase 2 Venture Trial of Dual GLP-1/GIP Receptor Agonist Vv2735 in Patients with Obesity

Viking Therapeutics, Inc. to Report Q2, 2023 Results on Jul 26, 2023

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Price target increased by 7.5% to US$31.50

Ligand's Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of Voyage Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis

Price target increased by 12% to US$30.80

Price target increased by 8.1% to US$29.30

Price target increased by 15% to US$21.80

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics, Inc. Provides an Update on Its Clinical Pipeline and Other Corporate Developments

Viking Therapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Viking Therapeutics, Inc. Announces Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Insufficient new directors

Price target decreased to US$17.33

Viking Therapeutics, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Viking Therapeutics: Playing Second Fiddle To Madrigal

Insufficient new directors

Viking Therapeutics, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Viking Therapeutics Announces FDA Lifted Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics, Inc.(NasdaqCM:VKTX) dropped from Russell 2000 Dynamic Index

Director recently bought US$111k worth of stock

Viking Therapeutics, Inc. to Report Q1, 2022 Results on Apr 27, 2022